Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore. The abstract is titled “Molecular Shielding of CD52 Retains Expression, Anti-Phagocytic Don’t Eat Me Function and Protects from Alemtuzumab-Mediated Depletion.” The study is the first showing that T cells expres